Inventor
David Alexander Learmonth
Inventor
Alfena, PT
Overview
Patents· 40 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes19%
C07CAcyclic or carbocyclic compounds4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C07BGeneral methods of organic chemistry3%
Y02PClimate change mitigation technologies in the production or processing of goods2%
A61LMethods or apparatus for sterilising materials or objects in general1%
C08BPolysaccharides1%
C08LCompositions of macromolecular compounds1%
PatentTitleYear
10,927,193Gellan gum-based hydrogels, methods and uses thereof202110,336,740Nitrocatechol derivatives as COMT inhibitors201910,065,944Administration regime for nitrocatechols201810,059,696Process for preparing 1,3-dihydroimidazole-2-thione derivatives20189,845,316Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol20179,745,290'Dosage regimen for COMT inhibitors'20179,643,929'Asymmetric catalytic reduction of oxcarbazepine'20179,630,955'Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor'20179,630,951'1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase'20179,550,759'Nitrocatechol derivatives as COMT inhibitors'20179,458,111'Process for the synthesis of substituted urea compounds'20169,446,012'Pharmaceutical compounds'20169,353,082'Pharmaceutical compounds'20169,346,751'Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives'20169,206,135'Asymmetric catalytic reduction of oxcarbazepine'20159,126,988'Intermediate for preparing a catechol-O-methyltransferase inhibitor'20158,975,410'Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4] oxadiazol-5-yl]-3-nitrobenzene-1,2-diol'20158,957,222'Process for preparing intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation'20158,907,099'Nitrocatechol derivatives as COMT inhibitors'20148,865,913'Crystalline forms and processes for their preparation'20148,710,239'Process for preparing synthetic intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation'20148,546,571'Catalytic hydrogenation of ene-carbamates'20138,536,203'Pharmaceutical compounds'20138,524,746'Dosage regimen for COMT inhibitors'20138,481,582'1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase'20138,367,821'Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation'20138,288,532'Asymmetric catalytic reduction of oxcarbazepine'20128,168,793'Nitrocatechol derivatives as COMT inhibitors'20128,158,666'Process for the preparation of (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-YL)-1,3-dihydroimidazole-2-thione'20127,999,100'Method for chiral inversion of (S)-(+)-and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof'20117,834,177'Method for preparation of 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide'20107,820,813'Method for preparation of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide'20107,259,271'Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation'20077,241,886'Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b, f/azepine-5-carboxamide and 10,11-dihydro-10-oxo-5h-dibenz/b, f/azepine-5-carboxamide'20077,189,846'Method for racemization of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5h-dibenz[B,F]azepine-5-carboxamide and optically enriched mixtures thereof'20077,125,904'Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation'20067,119,197'Method for preparation of (s)-(+)-and(r)-(-)10,11-dihydro-10-hydrodoxy-5h-dibenz/b,f/azephine-5-carboxamide'20067,005,553'Method for the nitration of phenolic compounds'20066,512,136'Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them'20035,866,566'Derivatives of 10, 11-Dihydro-10-OXO-5H-Dibenz/B,F/Azepine-5-carboxamide'1999Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1999–2012Patents assigned to PORTELA & CA SA (9)· patent assignee history
1999–2007Based in Maia, PT· patent location history
2006–2021Based in Alfena, PT· patent location history
2010–2018Patents assigned to BIAL PORTELA & CA SA (16)· patent assignee history
2010–2017Based in Valongo, PT· patent location history
2012–2016Patents assigned to LEARMONTH DAVID ALEXANDER (15)· patent assignee history
2012–2016Patents assigned to BELIAEV ALEXANDER (7)· patent assignee history
2013–2018Based in S. Mamede do Coronado, PT· patent location history
2015–2019Patents assigned to BIAL—PORTELA & CA S A (11)· patent assignee history
2017Based in Valonga, PT· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BIAL PORTELA & CA SA | 16 | 2010–2018 |
| LEARMONTH DAVID ALEXANDERself | 15 | 2012–2016 |
| BIAL—PORTELA & CA S A | 11 | 2015–2019 |
| PORTELA & CA SA | 9 | 1999–2012 |
| BELIAEV ALEXANDER | 7 | 2012–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Alfena, PT | 24 | 2006–2021 |
| Valongo, PT | 7 | 2010–2017 |
| S. Mamede do Coronado, PT | 4 | 2013–2018 |
| Maia, PT | 4 | 1999–2007 |
| Valonga, PT | 1 | 2017 |